139 related articles for article (PubMed ID: 17581316)
1. Induction of urokinase-type plasminogen activator, interleukin-8 and early growth response-1 by STI571 through activating mitogen activated protein kinase in human small cell lung cancer cells.
Yoshida C; Niiya K; Niiya M; Shibakura M; Asaumi N; Tanimoto M
Blood Coagul Fibrinolysis; 2007 Jul; 18(5):425-33. PubMed ID: 17581316
[TBL] [Abstract][Full Text] [Related]
2. Involvement of ERK1/2 and p38 MAP kinase in doxorubicin-induced uPA expression in human RC-K8 lymphoma and NCI-H69 small cell lung carcinoma cells.
Niiya M; Niiya K; Shibakura M; Asaumi N; Yoshida C; Shinagawa K; Teshima T; Ishimaru F; Ikeda K; Tanimoto M
Oncology; 2004; 67(3-4):310-9. PubMed ID: 15557793
[TBL] [Abstract][Full Text] [Related]
3. Pharmacologic mitogen-activated protein/extracellular signal-regulated kinase kinase/mitogen-activated protein kinase inhibitors interact synergistically with STI571 to induce apoptosis in Bcr/Abl-expressing human leukemia cells.
Yu C; Krystal G; Varticovksi L; McKinstry R; Rahmani M; Dent P; Grant S
Cancer Res; 2002 Jan; 62(1):188-99. PubMed ID: 11782377
[TBL] [Abstract][Full Text] [Related]
4. The insulin-like growth factor-I (IGF-I) receptor kinase inhibitor NVP-ADW742, in combination with STI571, delineates a spectrum of dependence of small cell lung cancer on IGF-I and stem cell factor signaling.
Warshamana-Greene GS; Litz J; Buchdunger E; Hofmann F; García-Echeverría C; Krystal GW
Mol Cancer Ther; 2004 May; 3(5):527-35. PubMed ID: 15141010
[TBL] [Abstract][Full Text] [Related]
5. Imatinib mesylate (STI571) enhances amrubicin-induced cytotoxic activity through inhibition of the phosphatidylinositol 3-kinase/Akt pathway in small cell lung cancer cells.
Suyama H; Igishi T; Ueda Y; Shigeoka Y; Kodani M; Morita M; Takeda K; Sumikawa T; Nakazaki H; Matsunami K; Matsumoto S; Shimizu E
Oncol Rep; 2010 Jan; 23(1):217-22. PubMed ID: 19956885
[TBL] [Abstract][Full Text] [Related]
6. The selective tyrosine kinase inhibitor STI571 inhibits small cell lung cancer growth.
Krystal GW; Honsawek S; Litz J; Buchdunger E
Clin Cancer Res; 2000 Aug; 6(8):3319-26. PubMed ID: 10955819
[TBL] [Abstract][Full Text] [Related]
7. Epidermal growth factor stimulates urokinase-type plasminogen activator expression in human gingival fibroblasts. Possible modulation by genistein and curcumin.
Smith PC; Santibañez JF; Morales JP; Martinez J
J Periodontal Res; 2004 Dec; 39(6):380-7. PubMed ID: 15491342
[TBL] [Abstract][Full Text] [Related]
8. Regulation of cellular proliferation, cytoskeletal function, and signal transduction through CXCR4 and c-Kit in small cell lung cancer cells.
Kijima T; Maulik G; Ma PC; Tibaldi EV; Turner RE; Rollins B; Sattler M; Johnson BE; Salgia R
Cancer Res; 2002 Nov; 62(21):6304-11. PubMed ID: 12414661
[TBL] [Abstract][Full Text] [Related]
9. Increased sensitivity to the platelet-derived growth factor (PDGF) receptor inhibitor STI571 in chemoresistant glioma cells is associated with enhanced PDGF-BB-mediated signaling and STI571-induced Akt inactivation.
Servidei T; Riccardi A; Sanguinetti M; Dominici C; Riccardi R
J Cell Physiol; 2006 Jul; 208(1):220-8. PubMed ID: 16575905
[TBL] [Abstract][Full Text] [Related]
10. Interleukin-17 modulates myoblast cell migration by inhibiting urokinase type plasminogen activator expression through p38 mitogen-activated protein kinase.
Kocić J; Santibañez JF; Krstić A; Mojsilović S; Ilić V; Bugarski D
Int J Biochem Cell Biol; 2013 Feb; 45(2):464-75. PubMed ID: 23183001
[TBL] [Abstract][Full Text] [Related]
11. Induction of TNF-alpha, uPA, IL-8 and MCP-1 by doxorubicin in human lung carcinoma cells.
Niiya M; Niiya K; Kiguchi T; Shibakura M; Asaumi N; Shinagawa K; Ishimaru F; Kiura K; Ikeda K; Ueoka H; Tanimoto M
Cancer Chemother Pharmacol; 2003 Nov; 52(5):391-8. PubMed ID: 12908082
[TBL] [Abstract][Full Text] [Related]
12. STI571 reduces TRAIL-induced apoptosis in colon cancer cells: c-Abl activation by the death receptor leads to stress kinase-dependent cell death.
Huang DY; Chao Y; Tai MH; Yu YH; Lin WW
J Biomed Sci; 2012 Mar; 19(1):35. PubMed ID: 22462553
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of platelet-derived growth factor-mediated proliferation of osteosarcoma cells by the novel tyrosine kinase inhibitor STI571.
McGary EC; Weber K; Mills L; Doucet M; Lewis V; Lev DC; Fidler IJ; Bar-Eli M
Clin Cancer Res; 2002 Nov; 8(11):3584-91. PubMed ID: 12429650
[TBL] [Abstract][Full Text] [Related]
14. SU11248 inhibits KIT and platelet-derived growth factor receptor beta in preclinical models of human small cell lung cancer.
Abrams TJ; Lee LB; Murray LJ; Pryer NK; Cherrington JM
Mol Cancer Ther; 2003 May; 2(5):471-8. PubMed ID: 12748309
[TBL] [Abstract][Full Text] [Related]
15. Growth inhibition and modulation of kinase pathways of small cell lung cancer cell lines by the novel tyrosine kinase inhibitor STI 571.
Wang WL; Healy ME; Sattler M; Verma S; Lin J; Maulik G; Stiles CD; Griffin JD; Johnson BE; Salgia R
Oncogene; 2000 Jul; 19(31):3521-8. PubMed ID: 10918610
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin pathway but not the MEK/ERK pathway attenuates laminin-mediated small cell lung cancer cellular survival and resistance to imatinib mesylate or chemotherapy.
Tsurutani J; West KA; Sayyah J; Gills JJ; Dennis PA
Cancer Res; 2005 Sep; 65(18):8423-32. PubMed ID: 16166321
[TBL] [Abstract][Full Text] [Related]
17. Tyrosine kinase inhibitor STI571 enhances thyroid cancer cell motile response to Hepatocyte Growth Factor.
Frasca F; Vigneri P; Vella V; Vigneri R; Wang JY
Oncogene; 2001 Jun; 20(29):3845-56. PubMed ID: 11439348
[TBL] [Abstract][Full Text] [Related]
18. Imatinib mesylate (STI571) interference with growth of neuroectodermal tumour cell lines does not critically involve c-Kit inhibition.
Te Kronnie G; Timeus F; Rinaldi A; Crescenzio N; Spinelli M; Rosolen A; Ricotti E; Basso G
Int J Mol Med; 2004 Sep; 14(3):373-82. PubMed ID: 15289888
[TBL] [Abstract][Full Text] [Related]
19. The selective tyrosine kinase inhibitor, STI571, inhibits growth of anaplastic thyroid cancer cells.
Podtcheko A; Ohtsuru A; Tsuda S; Namba H; Saenko V; Nakashima M; Mitsutake N; Kanda S; Kurebayashi J; Yamashita S
J Clin Endocrinol Metab; 2003 Apr; 88(4):1889-96. PubMed ID: 12679488
[TBL] [Abstract][Full Text] [Related]
20. Effect of PD 098059, a specific inhibitor of mitogen-activated protein kinase kinase, on urokinase expression and in vitro invasion.
Simon C; Juarez J; Nicolson GL; Boyd D
Cancer Res; 1996 Dec; 56(23):5369-74. PubMed ID: 8968087
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
